Propanc Health Group Corp (OTCMKTS:PPCH) a nascent healthcare firm concentrating on the growth of proprietary treatments for cancer talked about the fresh insights on the advancement and spread of carcinomas. The company said that the insights are highlighted in the British Journal of Cancer by most famous researchers from the ‘University of Glasgow’.
All these insights may have notable implications for PRP, the company’s lead product, as an innovative measure to control cancer spread which is stated as metastasis. As per a report, metastasis is one of the prime reasons of patient death from cancer.
What the report says?
As per the published report, regulated and strict controls on cell growth and migration is must for achieving healthy states of tissues. The problems are aggravated when the normal course is disturbed. The report defines carcinomas as the cancer spread from epithelial tissues that surrounds internal regions and organs in a human body.
One of the most significant features of carcinomas that are connected with ‘metastatic spread’ is the loss of activity of epithelial integrity. The condition is called as epithelial to mesenchymal transition, a stage when cancer cells spreads and become motile, giving birth to new tumors. The new measures are just a beginning and in the future EMT may offer inputs for treating cancer.
The views
Dr Julian Kenyon, Propanc’s CSO talked about the company’s lead candidate and disclosed that PRP makes use of two pancreatic proenzymes. They are named as trypsinogen and chymotrypsinogen. The two pancreatic proenzymes are in inactive state and when administered gets activated at the tumor place. The enzymes have capability to alter the cancer cell’s indicating lines. As a result, cells have to return to normal behavior resulting in death of cancer cells. PRP targets to reverse the EMT procedure.
On Friday’s trading session, Propanc share price surged 9.89% to close at $0.0200.
